Biotech Investment Analyst — Drug Asset & Company Assessment
Summary
Work as a biotech investment analyst creating and critiquing rubrics that evaluate commercial drugs and drug-development programs, assessing company and asset fundamentals including mechanism, clinical data, and competitive position. Apply specialist-fund experience across a pilot of ~5–10 biotech/pharma companies.
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We’re seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.
Responsibilities
-
Create and critique rubrics that analyze commercial drugs and drug-development programs
-
Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
-
Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
-
Apply your assessment across the pilot’s set of companies (~5–10)
Requirements
-
US-based biotech / healthcare investment analyst with a specialist-fund background
-
Familiarity with biotech/pharma development programs
-
Able to assess a drug asset and the company behind it end-to-end
-
5+ years evaluating biotech/pharma companies or assets
Engagement Details
-
Duration: Approximately 10–20 hours over a 1–2 week pilot
-
Remote — US-based
Why Participate
-
Help improve expert AI evaluation of drugs and drug-development programs
-
Recurring engagement for strong contributors